Analysts expect Editas Medicine, Inc. (NASDAQ:EDIT) to report $-0.39 EPS on March, 5.They anticipate $0.45 EPS change or 53.57% from last quarter’s $-0.84 EPS. After having $-0.32 EPS previously, Editas Medicine, Inc.’s analysts see 21.88% EPS growth. The stock increased 1.65% or $0.32 during the last trading session, reaching $19.75. About 1.37M shares traded or 40.65% up from the average. Editas Medicine, Inc. (NASDAQ:EDIT) has risen 12.45% since February 10, 2018 and is uptrending. It has outperformed by 12.45% the S&P500. Some Historical EDIT News: 06/03/2018 – Editas Medicine 4Q Loss/Shr 84c; 30/04/2018 – Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of; 23/05/2018 – Editas Closes Above 50-Day Moving Average: Technicals; 28/03/2018 – Editas Medicine Names James C. Mullen as Chmn of Bd of Directors; 28/03/2018 – EDITAS MEDICINE NAMES JAMES C. MULLEN AS CHAIRMAN OF BOARD; 18/05/2018 – Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates; 14/03/2018 – EDITAS MEDICINE INC EDIT.O : MORGAN STANLEY RAISES TARGET PRICE TO $43 FROM $28; 28/03/2018 – EDITAS MEDICINE INC – ALEXIS BORISY AND JOHN MENDLEIN, STEPPED DOWN FROM BOARD; 03/05/2018 – EDITAS MEDICINE INC – CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $359 MLN AS OF MARCH 31, 2018; 18/05/2018 – Editas Medicine: To File Investigational New Drug Application for EDIT-101 by Mid-2018
Anthem Inc (NYSE:ANTM) had a decrease of 1.87% in short interest. ANTM’s SI was 3.44 million shares in February as released by FINRA. Its down 1.87% from 3.51M shares previously. With 1.48M avg volume, 2 days are for Anthem Inc (NYSE:ANTM)’s short sellers to cover ANTM’s short positions. The SI to Anthem Inc’s float is 1.32%. The stock decreased 1.23% or $3.8 during the last trading session, reaching $304.25. About 1.74 million shares traded or 4.24% up from the average. Anthem, Inc. (NYSE:ANTM) has risen 23.71% since February 10, 2018 and is uptrending. It has outperformed by 23.71% the S&P500. Some Historical ANTM News: 04/04/2018 – JANA LISTS ANTHEM AMONG TOP 5 LONG POSITIONS: MONTHLY LETTER; 24/05/2018 – S-Curve Records Signs Eurovision Winner Netta’s Empowerment Anthem “Toy”; 01/05/2018 – ACEP Turns Up Criticism of Anthem’s Emergency Care Policy With a New Video Campaign; 25/04/2018 – Anthem 1Q Rev $22.54B; 23/05/2018 – ANTHEM, TO BUY ASPIRE HEALTH; 08/03/2018 – Health insurer Cigna to buy Express Scripts for about $53 bln; 25/04/2018 – Inside the Confidential N.F.L. Meeting to Discuss National Anthem Protests; 16/05/2018 – CIGNA: NO FIRM EXPRESSED INTEREST IN BUYING IT POST-ANTHEM DEAL; 22/05/2018 – SHAREHOLDERS HAD ACCUSED EXPRESS SCRIPTS OF INFLATING ITS SHARE PRICE BY CONCEALING ITS DETERIORATING RELATIONSHIP WITH ANTHEM, A BIG CUSTOMER; 25/05/2018 – Hartford Core Equity Adds Anthem, Exits Aetna, Cuts TJX
More notable recent Anthem, Inc. (NYSE:ANTM) news were published by: Seekingalpha.com which released: “Anthem Q4 2018 Earnings Preview – Seeking Alpha” on January 29, 2019, also Seekingalpha.com with their article: “Morgan Stanley bullish on Anthem after Q4 beat – Seeking Alpha” published on January 30, 2019, Seekingalpha.com published: “Anthem Is A Strong Buy For The Long Term – Seeking Alpha” on January 16, 2019. More interesting news about Anthem, Inc. (NYSE:ANTM) were released by: Seekingalpha.com and their article: “Tenet renews Anthem BC contract – Seeking Alpha” published on January 16, 2019 as well as Zacks.com‘s news article titled: “Is Anthem (ANTM) Stock Undervalued Right Now? – Zacks.com” with publication date: February 01, 2019.
Anthem, Inc., through its subsidiaries, operates as a health benefits firm in the United States. The company has market cap of $78.69 billion. It operates through three divisions: Commercial and Specialty Business, Government Business, and Other. It has a 21.44 P/E ratio. The firm offers a spectrum of network managed care health benefit plans to large and small employer, individual, Medicaid, and Medicare markets.
Among 11 analysts covering Anthem (NYSE:ANTM), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Anthem had 13 analyst reports since September 5, 2018 according to SRatingsIntel. As per Wednesday, September 5, the company rating was upgraded by Morgan Stanley. Cantor Fitzgerald maintained it with “Overweight” rating and $330 target in Tuesday, December 4 report. The firm has “Neutral” rating given on Tuesday, November 6 by Citigroup. Evercore upgraded the shares of ANTM in report on Thursday, January 3 to “Outperform” rating. Credit Suisse maintained Anthem, Inc. (NYSE:ANTM) on Thursday, November 1 with “Outperform” rating. The firm has “Outperform” rating given on Thursday, November 1 by BMO Capital Markets. Barclays Capital maintained Anthem, Inc. (NYSE:ANTM) on Thursday, November 1 with “Overweight” rating. The firm has “Neutral” rating by Citigroup given on Monday, September 10. The firm earned “Buy” rating on Monday, December 3 by Jefferies. Morgan Stanley maintained Anthem, Inc. (NYSE:ANTM) on Thursday, January 31 with “Overweight” rating.
More notable recent Editas Medicine, Inc. (NASDAQ:EDIT) news were published by: Nasdaq.com which released: “Should Sangamo’s Failure Make CRISPR Investors Nervous? – Nasdaq” on February 09, 2019, also Nasdaq.com with their article: “Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10) – Nasdaq” published on January 21, 2019, Nasdaq.com published: “Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know – Nasdaq” on February 01, 2019. More interesting news about Editas Medicine, Inc. (NASDAQ:EDIT) were released by: Nasdaq.com and their article: “Editas Medicine (EDIT) Gains But Lags Market: What You Should Know – Nasdaq” published on January 25, 2019 as well as Nasdaq.com‘s news article titled: “Is Sangamo’s Gene-Editing Approach a Bust? – Nasdaq” with publication date: February 09, 2019.
Editas Medicine, Inc. operates as a genome editing company. The company has market cap of $938.04 million. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It currently has negative earnings. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.